AAAAAA

   
Results: 1-9 |
Results: 9
Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia
Authors: Kaiser, R Tremblay, PB Schmider, J Henneken, M Dettling, M Muller-Oerlinghausen, B Uebelhack, R Roots, I Brockmoller, J
Citation: R. Kaiser et al., Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia, MOL PSYCHI, 6(2), 2001, pp. 179-185
Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry
Authors: Dettling, M Schaub, RT Mueller-Oerlinghausen, B Roots, I Cascorbi, I
Citation: M. Dettling et al., Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry, PHARMACOGEN, 11(2), 2001, pp. 135-141
Genetic determinants of clozapine-induced agranulocytosis: Recent results of HLA subtyping in a non-Jewish Caucasian sample
Authors: Dettling, M Cascorbi, I Roots, I Mueller-Oerlinghausen, B
Citation: M. Dettling et al., Genetic determinants of clozapine-induced agranulocytosis: Recent results of HLA subtyping in a non-Jewish Caucasian sample, ARCH G PSYC, 58(1), 2001, pp. 93-94
Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients
Authors: Dettling, M Sachse, C Brockmoller, J Schley, J Muller-Oerlinghausen, B Pickersgill, I Rolfs, A Schaub, RT Schmider, J
Citation: M. Dettling et al., Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients, PSYCHOPHAR, 152(1), 2000, pp. 80-86
Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia
Authors: Kaiser, R Konneker, M Henneken, M Dettling, M Muller-Oerlinghausen, B Roots, I Brockmoller, J
Citation: R. Kaiser et al., Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia, MOL PSYCHI, 5(4), 2000, pp. 418-424
Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: No association with myeloperoxidase and cytochrome P450206
Authors: Dettling, M Sachse, C Muller-Oerlinghausen, B Roots, I Brockmoller, J Rolfs, A Cascorbi, I
Citation: M. Dettling et al., Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: No association with myeloperoxidase and cytochrome P450206, PHARMACOPS, 33(6), 2000, pp. 218-220
Are there genetic determinants of olanzapine-induced agranulocytosis? Reply of the authors
Authors: Dettling, M
Citation: M. Dettling, Are there genetic determinants of olanzapine-induced agranulocytosis? Reply of the authors, PHARMACOPS, 33(5), 2000, pp. 198-199
Genetic determinants of drug-induced agranulocytosis: Potential risk of olanzapine?
Authors: Dettling, M Cascorbi, I Hellweg, R Deicke, U Weise, L Muller-Oerlinghausen, B
Citation: M. Dettling et al., Genetic determinants of drug-induced agranulocytosis: Potential risk of olanzapine?, PHARMACOPS, 32(3), 1999, pp. 110-112
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: Allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism
Authors: Sachse, C Ruschen, S Dettling, M Schley, J Bauer, S Muller-Oerlinghausen, B Roots, I Brockmoller, J
Citation: C. Sachse et al., Flavin monooxygenase 3 (FMO3) polymorphism in a white population: Allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism, CLIN PHARM, 66(4), 1999, pp. 431-438
Risultati: 1-9 |